MCID: BLR007
MIFTS: 53

Biliary Tract Neoplasm

Categories: Rare diseases, Cancer diseases, Liver diseases, Gastrointestinal diseases

Aliases & Classifications for Biliary Tract Neoplasm

MalaCards integrated aliases for Biliary Tract Neoplasm:

Name: Biliary Tract Neoplasm 12 28 14 69
Biliary Tract Cancer 72 49 51 69
Carcinoma of Extrahepatic Bile Duct 12 69
Extrahepatic Bile Duct Carcinoma 12 14
Extrahepatic Bile Duct Neoplasm 12 69
Malignant Tumor of Extrahepatic Bile Duct 69
Neoplasm of Extrahepatic Bile Ducts 12
Tumor of the Extrahepatic Bile Duct 12
Bile Duct Extrahepatic Carcinoma 51
Extrahepatic Bile Duct Cancer 12

Classifications:



Summaries for Biliary Tract Neoplasm

Disease Ontology : 12 A hepatobiliary benign neoplasm located in the biliary tract.

MalaCards based summary : Biliary Tract Neoplasm, also known as biliary tract cancer, is related to bile duct carcinoma and biliary papillomatosis. An important gene associated with Biliary Tract Neoplasm is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Metabolism of proteins and Endometrial cancer. The drugs Pancrelipase and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include the biliary tract, liver and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Cholangiocarcinoma, also known as bile duct cancer, is a form of cancer that is composed of mutated... more...

Related Diseases for Biliary Tract Neoplasm

Diseases related to Biliary Tract Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 bile duct carcinoma 29.9 CDX2 KRT7 MUC1 MUC2 MUC4 TP53
2 biliary papillomatosis 29.1 CDX2 HRAS KRAS KRT7 MUC1 MUC2
3 cholangiocarcinoma 27.9 CDX2 KRAS KRT7 MUC1 MUC2 MUC4
4 adenocarcinoma 27.9 CDKN2A HRAS KRAS MUC1 MUC4 SMAD4
5 extrahepatic bile duct adenocarcinoma 11.3
6 klatskin's tumor 11.3
7 extrahepatic bile duct small cell adenocarcinoma 11.3
8 extrahepatic bile duct adenoma 11.3
9 gallbladder adenoma 11.1
10 cap polyposis 10.5 MUC2 MUC4
11 pancreatic intraductal papillary-mucinous neoplasm 10.5 MUC1 MUC2
12 tumor of exocrine pancreas 10.4 MUC1 MUC2
13 colorectal cancer 1 10.4 MUC2 MUC4
14 malignant peritoneal mesothelioma 10.4 CDKN2A MUC1
15 brain stem astrocytic neoplasm 10.4 CDKN2A TP53
16 endometrial mucinous adenocarcinoma 10.4 CDKN2A MUC1
17 squamous cell carcinoma of the oropharynx 10.4 CDKN2A TP53
18 cholangiolocellular carcinoma 10.4 CDKN2A MUC1
19 sarcomatoid mesothelioma 10.4 CDKN2A MUC1
20 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
21 squamous cell carcinoma of the larynx 10.3 CDKN2A TP53
22 bartholin's gland benign neoplasm 10.3 CDKN2A TP53
23 pleomorphic liposarcoma 10.3 CDKN2A MUC1
24 ischemic fasciitis 10.3 CDKN2A MUC1
25 filamentary keratitis 10.3 MUC1 MUC4
26 anal squamous cell carcinoma 10.3 CDKN2A TP53
27 thyroid lymphoma 10.3 CDKN2A TP53
28 inverted transitional papilloma 10.3 CDKN2A KRT7
29 vulva squamous cell carcinoma 10.3 CDKN2A TP53
30 bone squamous cell carcinoma 10.3 CDKN2A TP53
31 plasmablastic lymphoma 10.3 CDKN2A MUC1
32 megaesophagus 10.3 CDKN2A TP53
33 scrotal carcinoma 10.3 CDKN2A TP53
34 mucinous intrahepatic cholangiocarcinoma 10.3 CDX2 MUC2
35 chordoid glioma 10.3 MUC1 TP53
36 melanomatosis 10.3 CDKN2A HRAS
37 vulval paget's disease 10.3 CDKN2A KRT7
38 oral leukoplakia 10.3 CDKN2A TP53
39 endocervical carcinoma 10.3 CDKN2A KRT7
40 anogenital venereal wart 10.3 CDKN2A TP53
41 balanitis xerotica obliterans 10.3 CDKN2A TP53
42 adenoid basal cell carcinoma 10.3 CDKN2A KRT7
43 cervix uteri carcinoma in situ 10.3 CDKN2A TP53
44 middle ear adenoma 10.3 KRT7 MUC1
45 endosalpingiosis 10.3 KRT7 MUC1
46 parachordoma 10.3 KRT7 MUC1
47 neuroendocrine tumor 10.3
48 malignant mixed mullerian tumor 10.3 KRT7 MUC1
49 nodular hidradenoma 10.3 KRT7 MUC1
50 chronic cholangitis 10.3 CDX2 MUC2

Comorbidity relations with Biliary Tract Neoplasm via Phenotypic Disease Network (PDN):


Acute Pancreatitis Cholangitis
Cholestasis Deficiency Anemia
Intrahepatic Gall Duct Cancer Pancreatic Cancer
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Biliary Tract Neoplasm:



Diseases related to Biliary Tract Neoplasm

Symptoms & Phenotypes for Biliary Tract Neoplasm

GenomeRNAi Phenotypes related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.36 HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.36 KRAS
3 Decreased viability GR00221-A-1 9.36 HRAS KRAS
4 Decreased viability GR00221-A-2 9.36 HRAS KRAS
5 Decreased viability GR00221-A-3 9.36 HRAS
6 Decreased viability GR00301-A 9.36 KRAS
7 Decreased viability GR00381-A-1 9.36 KRAS

MGI Mouse Phenotypes related to Biliary Tract Neoplasm:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.87 SMAD4 CDKN2A TP53 CDX2 HRAS KRAS
2 digestive/alimentary MP:0005381 9.8 SMAD4 CDKN2A TP53 CDX2 HRAS KRAS
3 endocrine/exocrine gland MP:0005379 9.7 SMAD4 CDKN2A TP53 CDX2 HRAS KRAS
4 homeostasis/metabolism MP:0005376 9.56 SMAD4 CDKN2A TP53 CDX2 HRAS KRAS
5 neoplasm MP:0002006 9.17 SMAD4 CDKN2A TP53 CDX2 HRAS KRAS

Drugs & Therapeutics for Biliary Tract Neoplasm

Drugs for Biliary Tract Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1 53608-75-6
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
7 Analgesics Phase 4,Phase 1
8 Analgesics, Non-Narcotic Phase 4,Phase 1
9 pancreatin Phase 4,Phase 2,Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Central Nervous System Depressants Phase 4
12 Gastrointestinal Agents Phase 4,Phase 2
13 Anesthetics Phase 4
14 Anesthetics, General Phase 4
15 Anesthetics, Inhalation Phase 4
16 Platelet Aggregation Inhibitors Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4
19 Antirheumatic Agents Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 arginine Nutraceutical Phase 4
23 Omega 3 Fatty Acid Nutraceutical Phase 4
24
Gemcitabine Approved Phase 2, Phase 3, Phase 1 95058-81-4 60750
25
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
26
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
27
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
28
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
29
Levoleucovorin Approved, Investigational Phase 2, Phase 3, Phase 1 68538-85-2
30
Cisplatin Approved Phase 2, Phase 3, Phase 1 15663-27-1 2767 441203 84093
31
Epirubicin Approved Phase 3,Phase 1,Phase 2 56420-45-2 41867
32
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605
33
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
34
Tegafur Approved, Investigational Phase 3,Phase 2,Phase 1 17902-23-7 5386
35
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
36
Citalopram Approved Phase 3 59729-33-8 2771
37
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3, Phase 1 59-30-3 6037
39
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
40 Anti-Infective Agents Phase 2, Phase 3, Phase 1
41 Antimetabolites Phase 2, Phase 3, Phase 1
42 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
43 Antiviral Agents Phase 2, Phase 3, Phase 1
44 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
48 Dermatologic Agents Phase 3,Phase 2,Phase 1
49 Photosensitizing Agents Phase 3,Phase 2,Phase 1
50 Calcium, Dietary Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 300)

# Name Status NCT ID Phase Drugs
1 Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction Unknown status NCT01514214 Phase 4
2 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
5 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
6 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
7 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
8 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
9 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
10 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Recruiting NCT02174575 Phase 4 Sevoflurane;Desflurane
11 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
12 The Effect of Individualized Precision Therapy Programs in Patients With BTC Not yet recruiting NCT02943031 Phase 4
13 X-MAS Biliary Study With Covered Biliary Stent Unknown status NCT01899976 Phase 3
14 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
15 Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Completed NCT00939848 Phase 2, Phase 3 gemcitabine;cisplatin;Placebo;cisplatin;cediranib;gemcitabine
16 Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Completed NCT01731821 Phase 3
17 Early Palliative Care on Quality of Life of Advanced Cancer Patients Completed NCT02988635 Phase 3
18 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
19 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
20 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
21 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
22 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
23 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
24 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
25 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
26 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
27 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
28 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
29 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
30 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
31 GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer Active, not recruiting NCT02182778 Phase 3 Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1
32 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
33 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
34 Study of SPARC1507 Not yet recruiting NCT02597465 Phase 3 SPARC1507;Reference1507
35 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Not yet recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
36 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Not yet recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
37 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
38 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
39 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
40 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
41 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
42 Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract Unknown status NCT02632019 Phase 1, Phase 2 Gemcitabine
43 Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm Unknown status NCT02528526 Phase 1, Phase 2 OXY111A
44 Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer Unknown status NCT02433639 Phase 2 TH-302 monotherapy
45 Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01494363 Phase 2 Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan
46 Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01234051 Phase 2 Docetaxel, Oxaliplatin
47 Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
48 SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Unknown status NCT01811277 Phase 2 SOX sequential S-1
49 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
50 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant

Search NIH Clinical Center for Biliary Tract Neoplasm

Genetic Tests for Biliary Tract Neoplasm

Genetic tests related to Biliary Tract Neoplasm:

# Genetic test Affiliating Genes
1 Biliary Tract Neoplasm 28

Anatomical Context for Biliary Tract Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Biliary Tract Neoplasm:

18
The Biliary Tract

MalaCards organs/tissues related to Biliary Tract Neoplasm:

38
Liver, Lung, Small Intestine, Pancreas, Testes, T Cells, Nk Cells

Publications for Biliary Tract Neoplasm

Articles related to Biliary Tract Neoplasm:

# Title Authors Year
1
Imaging features and appropriate treatment strategy of a rare biliary tract neoplasm. ( 23823837 )
2013
2
Epidemiological aspects of gallbladder and biliary tract neoplasm. ( 5008636 )
1972

Variations for Biliary Tract Neoplasm

Cosmic variations for Biliary Tract Neoplasm:

9 (show top 50) (show all 236)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 18
2 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,NS c.1475G>T p.R492L 18
3 COSM10656 TP53 biliary tract,bile duct,carcinoma,NS c.742C>T p.R248W 18
4 COSM44329 TP53 biliary tract,bile duct,carcinoma,NS c.470T>A p.V157D 18
5 COSM10777 TP53 biliary tract,bile duct,carcinoma,NS c.715A>G p.N239D 18
6 COSM45050 TP53 biliary tract,bile duct,carcinoma,NS c.871A>G p.K291E 18
7 COSM43687 TP53 biliary tract,bile duct,carcinoma,NS c.641A>G p.H214R 18
8 COSM10704 TP53 biliary tract,bile duct,carcinoma,NS c.844C>T p.R282W 18
9 COSM10663 TP53 biliary tract,bile duct,carcinoma,NS c.916C>T p.R306* 18
10 COSM10660 TP53 biliary tract,bile duct,carcinoma,NS c.818G>A p.R273H 18
11 COSM10654 TP53 biliary tract,bile duct,carcinoma,NS c.637C>T p.R213* 18
12 COSM44326 TP53 biliary tract,bile duct,carcinoma,NS c.706T>C p.Y236H 18
13 COSM45393 TP53 biliary tract,bile duct,carcinoma,NS c.793C>A p.L265M 18
14 COSM44114 TP53 biliary tract,bile duct,carcinoma,NS c.826G>A p.A276T 18
15 COSM10725 TP53 biliary tract,bile duct,carcinoma,NS c.701A>G p.Y234C 18
16 COSM43842 TP53 biliary tract,bile duct,carcinoma,NS c.770T>C p.L257P 18
17 COSM44823 TP53 biliary tract,bile duct,carcinoma,NS c.981T>G p.Y327* 18
18 COSM10731 TP53 biliary tract,bile duct,carcinoma,NS c.707A>G p.Y236C 18
19 COSM10662 TP53 biliary tract,bile duct,carcinoma,NS c.743G>A p.R248Q 18
20 COSM10722 TP53 biliary tract,bile duct,carcinoma,NS c.853G>A p.E285K 18
21 COSM43778 TP53 biliary tract,bile duct,carcinoma,NS c.713G>T p.C238F 18
22 COSM44426 TP53 biliary tract,bile duct,carcinoma,NS c.568C>G p.P190A 18
23 COSM44309 TP53 biliary tract,bile duct,carcinoma,NS c.440T>G p.V147G 18
24 COSM44785 TP53 biliary tract,bile duct,carcinoma,NS c.702C>G p.Y234* 18
25 COSM11582 TP53 biliary tract,bile duct,carcinoma,NS c.395A>G p.K132R 18
26 COSM43751 TP53 biliary tract,bile duct,carcinoma,NS c.673-1G>A p.? 18
27 COSM44523 TP53 biliary tract,bile duct,carcinoma,NS c.863A>G p.N288S 18
28 COSM43635 TP53 biliary tract,bile duct,carcinoma,NS c.536A>T p.H179L 18
29 COSM10727 TP53 biliary tract,bile duct,carcinoma,NS c.438G>A p.W146* 18
30 COSM44786 TP53 biliary tract,bile duct,carcinoma,NS c.694A>C p.I232L 18
31 COSM10648 TP53 biliary tract,bile duct,carcinoma,NS c.524G>A p.R175H 18
32 COSM43596 TP53 biliary tract,bile duct,carcinoma,NS c.841G>A p.D281N 18
33 COSM11090 TP53 biliary tract,bile duct,carcinoma,NS c.541C>T p.R181C 18
34 COSM10690 TP53 biliary tract,bile duct,carcinoma,NS c.473G>A p.R158H 18
35 COSM44262 TP53 biliary tract,bile duct,carcinoma,NS c.808T>C p.F270L 18
36 COSM11078 TP53 biliary tract,bile duct,carcinoma,NS c.1027G>T p.E343* 18
37 COSM10659 TP53 biliary tract,bile duct,carcinoma,NS c.817C>T p.R273C 18
38 COSM11356 TP53 biliary tract,bile duct,carcinoma,NS c.726C>G p.C242W 18
39 COSM43947 TP53 biliary tract,bile duct,carcinoma,NS c.614A>G p.Y205C 18
40 COSM10883 TP53 biliary tract,bile duct,carcinoma,NS c.731G>A p.G244D 18
41 COSM10672 TP53 biliary tract,bile duct,carcinoma,NS c.577C>T p.H193Y 18
42 COSM11355 TP53 biliary tract,bile duct,carcinoma,NS c.737T>C p.M246T 18
43 COSM44226 TP53 biliary tract,bile duct,carcinoma,NS c.380C>T p.S127F 18
44 COSM10893 TP53 biliary tract,bile duct,carcinoma,NS c.824G>A p.C275Y 18
45 COSM45025 TP53 biliary tract,bile duct,carcinoma,NS c.488A>C p.Y163S 18
46 COSM10738 TP53 biliary tract,bile duct,carcinoma,NS c.542G>A p.R181H 18
47 COSM44623 TP53 biliary tract,bile duct,carcinoma,NS c.487T>A p.Y163N 18
48 COSM44271 TP53 biliary tract,bile duct,carcinoma,NS c.688A>C p.T230P 18
49 COSM44463 TP53 biliary tract,bile duct,carcinoma,NS c.848G>T p.R283L 18
50 COSM10742 TP53 biliary tract,bile duct,carcinoma,NS c.578A>G p.H193R 18

Expression for Biliary Tract Neoplasm

Search GEO for disease gene expression data for Biliary Tract Neoplasm.

Pathways for Biliary Tract Neoplasm

Pathways related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 CDKN2A CDX2 MUC1 MUC2 MUC4 SMAD4
2
Show member pathways
12.86 CDKN2A HRAS KRAS SMAD4 TP53
3
Show member pathways
12.68 CDKN2A HRAS KRAS TP53
4 12.63 CDKN2A HRAS KRAS SMAD4 TP53
5
Show member pathways
12.41 CDKN2A HRAS KRAS TP53
6
Show member pathways
12.39 HRAS KRAS SMAD4 TP53
7 12.33 CDKN2A HRAS KRAS TP53
8
Show member pathways
12.31 HRAS KRAS MUC1 TP53
9 12.19 HRAS KRAS TP53
10
Show member pathways
12.18 HRAS KRAS MUC1 MUC2 MUC4
11
Show member pathways
12.14 MUC1 MUC2 MUC4
12 12.13 CDKN2A HRAS KRAS SMAD4 TP53
13 12.1 CDKN2A HRAS KRAS TP53
14 12.08 KRAS SMAD4 TP53
15
Show member pathways
12.06 HRAS KRAS TP53
16 12.03 KRAS SMAD4 TP53
17
Show member pathways
12.02 HRAS KRAS TP53
18
Show member pathways
12.01 HRAS KRAS TP53
19
Show member pathways
11.99 MUC1 MUC2 MUC4
20 11.98 CDKN2A HRAS KRAS TP53
21 11.97 HRAS KRAS SMAD4
22
Show member pathways
11.96 HRAS KRAS SMAD4
23 11.95 CDKN2A SMAD4 TP53
24 11.95 HRAS KRAS SMAD4
25 11.93 CDKN2A KRAS TP53
26
Show member pathways
11.92 HRAS KRAS TP53
27 11.92 HRAS KRAS TP53
28 11.87 HRAS KRAS TP53
29 11.85 HRAS KRAS TP53
30
Show member pathways
11.83 CDKN2A CDX2 HRAS KRAS MUC2 SMAD4
31
Show member pathways
11.81 MUC1 MUC2 MUC4
32 11.78 CDKN2A HRAS KRAS TP53
33 11.76 HRAS KRAS SMAD4
34
Show member pathways
11.74 CDKN2A HRAS KRAS SMAD4 TP53
35 11.73 CDKN2A HRAS SMAD4 TP53
36 11.54 HRAS KRAS TP53
37 11.53 HRAS KRAS TP53
38 11.42 CDKN2A HRAS KRAS TP53
39 11.41 CDKN2A HRAS KRAS SMAD4 TP53
40 11.18 HRAS KRAS
41
Show member pathways
11.17 HRAS KRAS
42
Show member pathways
11.12 HRAS KRAS
43 11.11 HRAS KRAS SMAD4
44 11.05 HRAS KRAS
45 11.03 HRAS KRAS
46 11.03 CDKN2A TP53
47
Show member pathways
11.02 CDKN2A TP53
48 10.99 MUC2 SMAD4
49 10.97 HRAS KRAS
50 10.72 HRAS KRAS

GO Terms for Biliary Tract Neoplasm

Cellular components related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.13 MUC1 SMAD4 TP53
2 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC4

Biological processes related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.8 CDKN2A HRAS SMAD4 TP53
2 axon guidance GO:0007411 9.73 HRAS KRAS SMAD4
3 positive regulation of gene expression GO:0010628 9.71 CDKN2A HRAS KRAS TP53
4 cell cycle arrest GO:0007050 9.69 CDKN2A HRAS TP53
5 negative regulation of cell growth GO:0030308 9.61 CDKN2A SMAD4 TP53
6 cell aging GO:0007569 9.57 HRAS TP53
7 cellular response to gamma radiation GO:0071480 9.55 HRAS TP53
8 cellular senescence GO:0090398 9.54 CDKN2A HRAS
9 regulation of long-term neuronal synaptic plasticity GO:0048169 9.52 HRAS KRAS
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 MUC1 TP53
11 positive regulation of cellular senescence GO:2000774 9.46 CDKN2A KRAS
12 replicative senescence GO:0090399 9.37 CDKN2A TP53
13 O-glycan processing GO:0016266 9.33 MUC1 MUC2 MUC4
14 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC2 MUC4
15 response to isolation stress GO:0035900 9.26 HRAS KRAS
16 Ras protein signal transduction GO:0007265 9.26 CDKN2A HRAS KRAS TP53
17 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC4

Sources for Biliary Tract Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....